adx earn numer event
clinic hold one trial concern pt
messag advaxi report financi close today financi
updat model note perhap salient point comment
made manag fda place clinic hold axal axalimogen
filolisbac plu imfinzi phase combin studi patient r/r hpv-associ
cervic cancer hpv-associ head neck cancer base hold
lower price target
clinic hold due recent submit safeti report fda regard
death patient februari compani notifi clinic hold march
complic involv respiratori failur follow sixth combin cycl
trial note patient dose imfinzi axal dose everi two
week imfinzi everi four week axal day drug given
imfinzi gener first drug given follow axal howev one case hypo-
tension occur deliveri second drug sequela lead respiratori
failur occur note affect patient r/r cervic cancer
trial almost year without complic patient receiv dose imfinzi
dose axal adx partner astrazeneca azn imfinzi
fda plan work close site investig review event resolv
clinic hold howev emphas clinic hold seem affect
on-going axal trial date patient treat io agent combin
trial keytruda singl case grade event
made adjust model base result manag
commentari made earn call afternoon lower price target
adx decreas pt reflect recent fda clinic hold
compani phase combin trial axalimogen filolisbac axal astrazeneca
azn imfinzi treatment advanc recurr refractori human papillomaviru
hpv -associ cervic cancer hpv-associ head neck cancer result
shift expect market entri compani product candid cervic
cancer previous late addit shift market entri
product candid cancer previous earli
lower estim expens base comment made manag
surround research develop also account potenti financ
first half given compani expect cash runway
maintain buy rate adx valuat base forward sum-
of-the-part dcf includ revenu adxs-hpv cervic anal head
neck cancer set royalti revenu net cash valuat appli unchang
page analyst certif import disclosur
discount rate unchang termin growth rate reflect compani
collabor profil proprietari listeria vector platform
valuat risk
valuat price target base forward sum-of-the-part dcf
includ revenu adxs-hpv cervic anal head neck cancer set
royalti revenu net cash collabor trial astrazeneca azn merck
well adxs-psa product candid yet includ
project could repres substanti upsid analysi valuat
appli discount rate termin growth rate reflect compani
collabor profil proprietari listeria vector platform
risk risk price target rate includ limit neg
clinic trial result either relat safeti efficaci adx drug candid failur
gain /eu regulatori approv emerg clinic result competit therapi
hpv-associ cancer challeng adx intellectu properti posit
page analyst certif import disclosur
million except per-shar figur
page analyst certif import disclosur
